Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects

NCT01596712 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

209

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

DRUG: QGE031
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals